Kura May Have Found A Place For Tipifarnib In Head-And-Neck Cancer
The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.
You may also be interested in...
Emerging Company Profile: The US biotech is advancing a pipeline of precision medicines targeting menin and farnesyltransferase for liquid and solid tumors, respectively, building on the work of two pioneering companies in the KRAS space.
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
Since using a reverse-merger last year to go public, Kura Oncology has resurrected an abandoned Janssen cancer candidate and raised $46.5m in an IPO. CEO Troy Wilson spoke with Scrip about the firm's efforts toward precision medicine in cancer.